Delcath Systems Reports Third Quarter 2023 Results and Provides Business Update

[ad_1] NEW YORK, Nov. 13, 2023 /PRNewswire/ — Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers…

Delcath Systems Announces an Independent Investigator Presentation at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Meeting

[ad_1] A Retrospective Comparative Study of SIRT and CS-PHP for Liver Targeted Therapy of Patients with Metastatic Uveal Melanoma NEW YORK, Aug. 29, 2023 /PRNewswire/ — Delcath Systems, Inc. (Nasdaq:…

Delcath Systems Reports Second Quarter 2023 Results and Provides Business Update

[ad_1] NEW YORK, Aug. 9, 2023 /PRNewswire/ — Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers…